The small biopharma company Trevena (TRVN) suffered a setback Thursday after a panel of outside experts convened by the Food and Drug Administration recommended against the approval of its intravenous painkiller. The 7-8 vote means the FDA is almost guaranteed to reject the painkiller, called oliceridine, at or near its review decision deadline of Nov. 2.
But Trevena may have other equally serious problems to deal with in the near future. Earlier this week, investors were told that Trevena’s management, led by CEO Maxine Gowen, misled them for years about the company’s dealings with the FDA.
Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research Subscriber-only networking events and panel discussions across the country Monthly subscriber-only live chats with our reporters and experts in the field Discounted tickets to industry events and early-bird access to industry reports
Adam Feuerstein
Senior Writer, Biotech
Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street.
Sumber: https://bit.ly/2A6kgt3
Comments
Post a Comment